Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

Nat Commun. 2019 Sep 11;10(1):4109. doi: 10.1038/s41467-019-11893-4.

Abstract

The inhibitory receptors PD-1, Tim-3, and Lag-3 are highly expressed on tumor-infiltrating lymphocytes and compromise their antitumor activity. For efficient cancer immunotherapy, it is important to prevent chimeric antigen receptor T (CAR-T)-cell exhaustion. Here we downregulate these three checkpoint receptors simultaneously on CAR-T cells and that show the resulting PTL-CAR-T cells undergo epigenetic modifications and better control tumor growth. Furthermore, we unexpectedly find increased tumor infiltration by PTL-CAR-T cells and their clustering between the living and necrotic tumor tissue. Mechanistically, PTL-CAR-T cells upregulate CD56 (NCAM), which is essential for their effector function. The homophilic interaction between intercellular CD56 molecules correlates with enhanced infiltration of CAR-T cells, increased secretion of interferon-γ, and the prolonged survival of CAR-T cells. Ectopically expressed CD56 promotes CAR-T cell survival and antitumor response. Our findings demonstrate that genetic blockade of three checkpoint inhibitory receptors and the resulting high expression of CD56 on CAR-T cells enhances the inhibition of tumor growth.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Apoptosis
  • CD56 Antigen / metabolism*
  • Cell Line, Tumor
  • Female
  • HEK293 Cells
  • Humans
  • Immunotherapy, Adoptive
  • Mice
  • Neoplasms / drug therapy
  • Neoplasms / immunology*
  • Neoplasms / therapy*
  • Protein Engineering*
  • Receptor, ErbB-2 / metabolism
  • Receptors, Chimeric Antigen / metabolism*

Substances

  • Antineoplastic Agents
  • CD56 Antigen
  • Receptors, Chimeric Antigen
  • Receptor, ErbB-2